NASDAQ$MDGL
Madrigal Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Madrigal reported first-quarter 2024 financial results and provided corporate updates.
Madrigal Pharmaceuticals reported no revenue for Q1 2024 as Rezdiffra shipments began in April. The company's cash, cash equivalents, and marketable securities totaled $1.1 billion as of March 31, 2024, bolstered by a recent public offering. Madrigal received FDA approval for Rezdiffra and is focused on its commercial launch.
- Received U.S. FDA approval of Rezdiffra for treating noncirrhotic NASH with moderate to advanced liver fibrosis.
- Product shipped and first patients received Rezdiffra in April 2024.
- Raised $690 million in gross proceeds from an upsized public offering.
- Reported cash, cash equivalents, and marketable securities of $1.1 billion at March 31, 2024.
Headline financials
Revenue & EPS history
Madrigal · Revenue · Quarterly
$0
Forward guidance
Madrigal is focused on executing the first launch of Rezdiffra, partnering with the NASH community to establish treatment pathways and laying the groundwork for long-term leadership.
Tailwinds
- Rezdiffra is the first and only FDA-approved therapy for NASH.
- Rezdiffra has demonstrated unprecedented efficacy in a pivotal Phase 3 trial.
- Madrigal estimates 1.5 million patients have been diagnosed with NASH in the U.S.
- Strong label positions Rezdiffra as a foundational therapy for NASH.
- Experienced team executing on U.S. specialty launch.
Headwinds
- No revenue was booked in the first quarter.
- First-quarter operating expenses were $152.0 million, compared to $78.3 million in the comparable prior year period.
- First-quarter R&D expense was $71.2 million, compared to $62.2 million in the comparable prior year period.
- First-quarter SG&A expense was $80.8 million, compared to $16.2 million in the comparable prior year period.
- The company faces challenges with the commercial launch of a new product, particularly without prior commercial experience.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.6%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+7.8%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+48.0%
Q3 2024
Best reaction
-23.3%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -1.2% | -3.2% | |
| Q4 2025 | -11.1% | -10.5% | -10.2% | |
| Q3 2025 | +7.8% | +18.7% | +42.2% | |
| Q1 2025 | -1.9% | -11.6% | -17.6% | |
| Q4 2024 | +15.0% | +1.3% | +5.9% | |
| Q3 2024 | +48.0% | +56.4% | +52.0% | |
| Q2 2024 | -8.6% | -9.2% | -8.5% | |
| Q1 2024 | -11.7% | -12.9% | +2.5% | |
| Q4 2023 | -1.5% | +2.8% | +11.4% | |
| Q3 2023 | +3.6% | -5.5% | +61.1% | |
| Q2 2023 | -6.0% | -4.5% | +6.4% | |
| Q1 2023 | -5.4% | -5.2% | -12.8% | |
| Q4 2022 | -5.4% | -7.1% | -19.6% | |
| Q3 2022 | -6.7% | -10.1% | +12.8% | |
| Q2 2022 | +22.8% | +12.1% | +10.8% | |
| Q1 2022 | -0.2% | +1.8% | +15.0% | |
| Q4 2021 | +7.9% | +13.1% | +9.2% | |
| Q3 2021 | -0.5% | -1.6% | -16.6% | |
| Q2 2021 | +7.5% | +0.8% | -4.5% | |
| Q1 2021 | +0.7% | +2.3% | -22.0% | |
| Q4 2020 | -1.3% | -6.9% | -5.3% | |
| Q3 2020 | -6.8% | -2.2% | -10.9% | |
| Q2 2020 | -1.1% | -2.2% | +2.3% | |
| Q1 2020 | +2.9% | +25.1% | +27.6% | |
| Q4 2019 | -2.5% | +2.6% | -19.7% | |
| Q3 2019 | +0.1% | +7.9% | +22.1% | |
| Q2 2019 | +2.0% | +2.0% | +9.8% | |
| Q1 2019 | +0.2% | -3.4% | -8.0% | |
| Q4 2018 | -2.4% | +3.1% | -6.9% | |
| Q3 2018 | +5.2% | -7.8% | -39.7% | |
| Q2 2018 | -1.0% | -5.9% | -11.0% | |
| Q1 2018 | -0.0% | +2.2% | +138.3% | |
| Q4 2017 | -16.4% | -20.4% | -15.8% | |
| Q3 2017 | -0.2% | -5.7% | +84.7% | |
| Q2 2017 | -0.8% | +1.7% | +13.5% | |
| Q1 2017 | +2.1% | +4.5% | -0.3% | |
| Q4 2016 | -2.2% | -4.9% | +6.8% | |
| Q3 2016 | +5.3% | +2.4% | -1.4% | |
| Q2 2016 | +3.8% | +11.5% | +1.9% | |
| Q1 2016 | +10.5% | — | — | |
| Q4 2015 | -23.3% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | -3.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | -6.1% | — | — | |
| Q3 2014 | +10.6% | — | — | |
| Q2 2014 | +0.5% | — | — | |
| Q1 2014 | +3.3% | — | — | |
| Q4 2013 | -10.1% | — | — | |
| Q3 2013 | +0.9% | — | — | |
| Q2 2013 | -4.2% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | -5.0% | — | — | |
| Q3 2012 | -5.2% | — | — | |
| Q2 2012 | +0.3% | — | — | |
| Q1 2012 | -11.2% | — | — | |
| Q4 2011 | +0.2% | — | — | |
| Q4 2009 | +0.2% | — | — | |
| Q3 2011 | +4.4% | — | — | |
| Q2 2011 | -10.1% | — | — | |
| Q4 2010 | -10.1% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q3 2010 | -6.1% | — | — | |
| Q2 2010 | -5.6% | — | — | |
| Q1 2010 | -16.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro